The team is specifically focused on bacterias that adhere to the surfaces of orthopedic implants, sometimes requiring revision or replacement surgeries.
Implant-associated hip and knee replacement infections impact 1 in every 100 patients, costing the U.S. health system billions, according to a Jan. 3 press release.
When developing their infection solution, the team factored in three criteria for this design. First, avoid changing the implant manufacturing process. Second, be customizable and the third priority was surgical efficiency.
Dr. Bernthal and Dr. Segura designed a surface modification platform that could be applied to implants during surgery to kill or slow microorganism growth.
Surgeons can combine the surface modification with an antimicrobial or antibiotic of their choosing and apply it directly onto an implant. In studies, coated implants prevented infections in 100% of mouse models.
Researchers are now working with the FDA to set up clinical trials in human patients.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
